Aromatic Amino Acid Metabolism as a Metabolic–Immune Link in Multiple Sclerosis
Multiple sclerosis (MS) is conventionally understood as an immune-mediated disorder characterized by inflammation, demyelination, axonal injury, and progressive neurodegeneration within the central nervous system. Nevertheless, genetic susceptibility and immune dysregulation alone do not fully explain the marked heterogeneity of the disease. Environmental exposures, dietary patterns, intestinal microbial activity, cellular energy demands, and pharmacological treatments may all influence disease onset and progression. In the study “Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism,” Fitzgerald and colleagues investigated whether circulating metabolites could provide an integrated molecular record of these interacting processes. The central premise was that the plasma or serum metabolome reflects the combined influence of host genetics, immune-cell activity, diet, organ function, and gut microbial metabolism. The graphical abstract on page 1 summarizes this systems-level strategy: circulating metabolomics was connected with clinical disability, single-cell transcriptomics, and experimental analysis of human monocytes. By integrating these complementary data layers, the authors sought not merely to identify diagnostic differences but to determine whether specific metabolic disturbances might participate functionally in MS pathophysiology.
A Large-Scale Multi-Omic Study Design
The investigators analyzed 954 metabolomic profiles obtained from 756 individuals, including 637 samples from people with MS and 317 samples from healthy controls. Following quality-control procedures, 269 metabolites were considered reliably measured. The MS cohort included individuals with relapsing-remitting and progressive disease, a broad age distribution, variable disability, and several disease-modifying treatment exposures. The researchers first developed an overall metabolic dysfunction score to quantify how strongly each participant’s metabolomic profile diverged from the healthy reference distribution. They then examined individual metabolites, predefined biochemical pathways, data-driven metabolite networks generated through weighted correlation analysis, and metabolic reactions represented in the MetaCyc database. Clinical relevance was evaluated using the Expanded Disability Status Scale, cane use, the age-related MS severity score, and optical coherence tomography measurements of retinal ganglion cell and inner plexiform layer thickness. To extend the metabolomic observations to the cellular level, the authors reanalyzed publicly available single-cell RNA-sequencing data from blood and cerebrospinal fluid. Finally, selected aromatic amino acid metabolites were applied to human immune cells in vitro to test their effects on inflammatory cytokine production and endocytosis.
A Distinct Metabolic Signature Dominated by Aromatic Amino Acids
The principal metabolomic finding was a substantial disturbance in aromatic amino acid metabolism. Aromatic amino acids—particularly phenylalanine, tyrosine, and tryptophan—serve as substrates for numerous host and microbial reactions that generate neuroactive, immunomodulatory, or potentially toxic compounds. People with MS displayed markedly lower concentrations of several lactate derivatives produced through reductive metabolic pathways, including phenyllactate, 3-(4-hydroxyphenyl)lactate, and indolelactate. Phenyllactate showed one of the largest differences between the groups, while tryptophan, tyrosine, phenylpyruvate, 4-hydroxyphenylpyruvate, and imidazole lactate were also reduced. These alterations remained broadly consistent after restricting analyses according to treatment status, disease subtype, age, and sample type, suggesting that they were not readily attributable to a single disease-modifying therapy or analytical batch. The pathway-level analysis shown in Figure 1 further demonstrated that the disturbance was not limited to isolated molecules; aromatic and branched-chain amino acids formed coordinated networks that differed between MS and healthy control samples. Additional abnormalities were identified in branched-chain amino acid, bile acid, xanthine, acetylated amino acid, and carnitine-associated pathways, indicating that MS is accompanied by broad systemic metabolic reorganization rather than one isolated biochemical defect.
Metabolic Balance Is Associated with Neurological Disability
A particularly important contribution of the study was its demonstration that metabolic abnormalities were related to disease severity. Participants who used a cane exhibited the greatest overall metabolic dysfunction, and reductions in several aromatic amino acid metabolites were associated with higher disability scores. In contrast, increased concentrations of p-cresol sulfate, p-cresol glucuronide, phenylacetylglutamine, and related compounds were associated with greater impairment. These molecules are generated largely through oxidative microbial metabolism of tyrosine, phenylalanine, and tryptophan and have been described as metabotoxins because they may promote inflammatory, vascular, renal, or cellular dysfunction when present at elevated concentrations. The authors therefore examined ratios between oxidative products and reductive lactate products. As illustrated in Figure 2 on page 10, higher phenylacetylglutamine-to-phenyllactate, p-cresol-to-hydroxyphenyllactate, and indole acetate-to-indolelactate ratios were associated with more severe disability. Similar relationships were observed with retinal measurements obtained by optical coherence tomography, providing an imaging-based correlate of neuroaxonal injury. These results support a model in which clinical severity is associated not simply with the absolute abundance of one metabolite, but with a shift in the direction of aromatic amino acid processing—from potentially immunoregulatory reductive products toward potentially harmful oxidative products.
Single-Cell Transcriptomics Identifies Monocytes as a Relevant Cellular Compartment
The transcriptomic component provided an independent layer of biological evidence. By reanalyzing single-cell RNA-sequencing datasets from peripheral blood and cerebrospinal fluid, the investigators examined whether genes involved in aromatic amino acid metabolism were differentially expressed in specific immune-cell populations. The strongest abnormalities were detected in monocyte clusters, including populations represented in both blood and cerebrospinal fluid. Aromatic amino acid metabolic pathway activity was generally lower in monocytes from people with MS than in corresponding cells from healthy controls. The investigators also evaluated gene networks associated with the aryl hydrocarbon receptor and hydroxycarboxylic acid receptor 3. These receptors are biologically relevant because several reductive aromatic amino acid metabolites can activate them and promote anti-inflammatory or homeostatic cellular responses. Expression of aryl hydrocarbon receptor network genes was significantly reduced in MS monocytes, whereas the reduction in the hydroxycarboxylic acid receptor 3 network did not reach statistical significance. The convergence of circulating metabolite measurements and cell-specific gene expression strengthens the biological interpretation of the findings. It suggests that altered metabolite availability may occur alongside changes in the ability of innate immune cells to produce, sense, or respond to aromatic amino acid derivatives.
Metabolites Directly Modify Human Monocyte Function
The in vitro experiments moved the investigation beyond association by demonstrating that selected metabolites could directly alter human monocyte behavior. Exposure to indole acetate, an oxidative tryptophan-derived metabolite associated with greater disability, increased tumor necrosis factor-α production by CD14-high monocytes in a dose-dependent manner. Phenylacetylglutamine and indole acetate also increased interleukin-6 production in a subset of experiments. Conversely, indolelactate—a reductive tryptophan-derived metabolite that was reduced in people with MS—produced a more immunoregulatory functional profile. Treatment with indolelactate reduced monocyte production of interleukin-6 and interleukin-1β and increased dextran endocytosis, a function commonly associated with homeostatic or less inflammatory myeloid-cell states. Phenyllactate did not produce an equivalent increase in endocytosis, demonstrating that metabolites within the same broad biochemical category are not functionally interchangeable. Collectively, these experiments offer a plausible mechanistic bridge between systemic metabolism and neuroinflammation: a reduction in protective lactate derivatives, combined with an increase in inflammatory oxidative metabolites, could bias monocytes toward enhanced cytokine production and diminished homeostatic function. Because monocytes and related myeloid cells can enter the central nervous system and contribute to lesion development, such metabolic programming may be relevant to both peripheral and compartmentalized inflammation.
Scientific Significance, Limitations, and Translational Outlook
The study establishes aromatic amino acid metabolism as a candidate interface connecting the intestinal microbiome, systemic metabolism, innate immunity, and neurological disability in MS. Its principal strength lies in the convergence of several methodological approaches: a relatively large metabolomic cohort, pathway and network analyses, clinical and imaging outcomes, cell-type-resolved transcriptomics, and functional immune-cell experiments. Nevertheless, the observational metabolomic data cannot establish whether the metabolic shift causes disability, results from advanced disease, or reflects correlated factors such as diet, microbial composition, renal clearance, physical activity, medication exposure, or immune activation. The transcriptomic datasets were obtained from previously published cohorts rather than from the same individuals who underwent metabolomic profiling, and the in vitro experiments cannot fully reproduce the concentrations, cellular interactions, or chronic exposures present in vivo. Consequently, the findings do not yet justify supplementation with indolelactate, dietary manipulation, microbiome-directed treatment, or clinical use of metabolite ratios as biomarkers. Prospective longitudinal cohorts, paired microbiome–metabolome studies, isotope-tracing experiments, and controlled intervention studies will be required to determine causality. Even with these qualifications, the work provides a compelling framework in which MS progression may be influenced by the balance between immunomodulatory and metabotoxic products of aromatic amino acid metabolism, thereby identifying a biologically coherent pathway for future biomarker and therapeutic research.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Fitzgerald, K. C., Smith, M. D., Kim, S., Sotirchos, E. S., Kornberg, M. D., Douglas, M., ... & Bhargava, P. (2021). Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism. Cell Reports Medicine, 2(10).
